Takeda Lifts FY2026 Net Profit Forecast 25.9% to JPY 209B on Strong H1
TAK sits 54% above its 52-week low of $12.99.
Summary
Takeda raised FY2026 net profit guidance 25.9% to JPY 209.0 billion and reported H1 net profit of JPY 305.7 billion, though the beat leans on yen weakness and a JPY 53.3 billion tax benefit while constant-currency guidance still calls for declines.
Key Events · Earnings and Guidance · TAK
-
FY2026 Net Profit Forecast Raised 25.9%
Net profit attributable to owners lifted to JPY 209.0 billion from JPY 166.0 billion, and reported EPS to JPY 131.28 from JPY 104.26; revenue forecast up JPY 60.0 billion to JPY 4,700.0 billion.
-
H1 Net Profit JPY 305.7 Billion, Up 171.6%
Operating profit rose 60.4% to JPY 406.7 billion, helped by JPY 118.3 billion lower amortization and impairment charges and yen depreciation; income tax expense fell JPY 53.3 billion on deferred tax asset reassessment.
-
Constant-Currency Guidance Still Negative
Core Operating Profit guidance revised to mid-single-digit % decline from 5%-8% decline, and Core EPS to low-teens % decline from mid-teens %; H1 revenue was down 1.0% at constant exchange rates.
-
Interim Dividend JPY 102 Per Share
Board approved the interim dividend payable December 1, 2026; the full-year projection of JPY 204 per share is unchanged.
Analysis · TAK · Life Sciences
Takeda's H1 net profit jumped 171.6% to JPY 305.7 billion, but most of that is a low base and a JPY 53.3 billion tax benefit rather than an operating step-change — operating profit rose 60.4% to JPY 406.7 billion largely on yen weakness and JPY 118.3 billion lower amortization and impairment charges. The more consequential item is the raised full-year forecast: net profit attributable to owners goes to JPY 209.0 billion from JPY 166.0 billion, a 25.9% increase, and reported EPS to JPY 131.28 from JPY 104.26. Against that, the constant-currency guidance still points down — Core Operating Profit now seen mid-single-digit % lower and Core EPS low-teens % lower for the year, so the raise is an FX and tax story, not underlying growth. H1 revenue fell 1.0% at constant exchange rates even as it rose 8.4% as reported.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 31% of the 1656 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.01%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TAK was trading at $19.96 on NYSE in the Life Sciences sector, with a market capitalization of approximately $63.8B. The 52-week trading range was $12.99 to $20.55. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.